干细胞是一种药物吗? 干细胞研究和开发的监管
1College of Physicians and Surgeons of Columbia University, Department of Pharmacology, 630 W 168 St, PH 7West-321, New York, NY 10032, USA. mrr1@columbia.edu
干细胞研究面临着监管混乱,因为不同的意见和监督. 本分析探讨了心血管干细胞治疗的社会框架,风险,益处和监管方法.
科学领域:
- 生物医学科学 生物医学科学
- 监管科学 监管科学
背景情况:
- 干细胞研究及其临床应用是公众和专业人士激烈辩论的主题.
- 缺乏中央监管机构,导致对干细胞治疗的监督产生混乱.
更多相关视频
12:32High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
11:24Measuring DNA Damage and Repair in Mouse Splenocytes After Chronic In Vivo Exposure to Very Low Doses of Beta- and Gamma-Radiation
Published on: July 4, 2015
相关概念视频
05:51Measuring Diaphragm Thickness and Function Using Point-of-Care Ultrasound
08:47Oral Health Assessment by Lay Personnel for Older Adults
05:17Preparation of High-Quality Fermented Fish Product
12:32High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
11:24Measuring DNA Damage and Repair in Mouse Splenocytes After Chronic In Vivo Exposure to Very Low Doses of Beta- and Gamma-Radiation
04:57Proper Care and Cleaning of the Microscope
